Sunho Biologics, Inc. (SUNHO BIO-B) submitted its Monthly Return for the period ending 31 March 2026, confirming a stable capital structure and full compliance with Hong Kong Exchange listing requirements. The filing was lodged on 09 April 2026.

Authorised Share Capital • Remained at 200.00 million ordinary shares with a par value of USD 0.0005 each, equivalent to USD 0.10 million. No changes were recorded during the month.

Issued Shares • Outstanding ordinary shares stayed at 156.67 million. • The company held no treasury shares, and there were no share issuances, cancellations, or repurchases in March.

Public Float • Management affirmed adherence to the 25% minimum public-float threshold specified under Main Board Rule 13.32B.

Capital Instruments and Dilution Events • The return reported no outstanding or new share options, warrants, convertibles, or other equity-linked instruments.

Governance • The document was signed by Chairman and Executive Director Zhang Feng, confirming the accuracy of the disclosed information.